Vemlidy® (tenofovir alafenamide) – Expanded indication
October 17, 2022 - The FDA approved Gilead’s Vemlidy (tenofovir alafenamide), for the treatment of chronic hepatitis B virus (HBV) infection in adults and pediatric patients 12 years of age and older with compensated liver disease.
Download PDF
